Читать книгу Complementary and Alternative Medicine (CAM) Supplement Use in People with Diabetes: A Clinician's Guide - Laura Shane-McWhorter - Страница 57

A 6-week pilot study of 18 patients with type 2 diabetes compared 2 g and 4 g caiapo to placebo.¹¹⁹ Fasting glucose decreased from 158 mg/dl (8.8 mmol/l) to 151 mg/dl (8.4 mmol/l) with low-dose caiapo and from 149 mg/dl (8.3 mmol/l) to 130 mg/dl (7.2 mmol/l) with the higher dose (P < 0.05 vs. baseline for the higher dose). The lower dose resulted in unchanged A1C, but A1C decreased from 7.1% to 6.8% with the higher dose (P value not significant). Total and LDL cholesterol also decreased in patients on the higher dose (from 192 mg/dl [5.0 mmol/l] to 172 mg/dl [4.4 mmol/l], P < 0.05; and 120 mg/dl [3.1 mmol/l] to 105 mg/dl [2.7 mmol/l], P < 0.05, respectively).

Another 3-month randomized, double-blind, placebo-controlled trial was conducted in 61 patients with type 2 diabetes who were mostly diet-treated.¹¹⁶ Thirty were placed on 4 g/day of caiapo, and 31 were placed on placebo. A1C declined from 7.2% to 6.7% (P < 0.001) in those taking caiapo, but increased from 7.04 % at baseline to 7.1% in the placebo group. Fasting glucose declined from 144 mg/dl (8.0 mmol/l) to 129 mg/dl (7.2 mmol/l; P < 0.001), and 2-hour postprandial glucose declined from 193 mg/dl (10.7 mmol/l) to 163 mg/dl (9.1 mmol/l; P < 0.001). Mean cholesterol was significantly lower in the caiapo group than in the placebo group (215 mg/dl [5.6 mmol/l] vs. 249 mg/dl [6.4 mmol/l], P < 0.05). Weight also decreased by 3.7 kg in the caiapo group (P < 0.0001 vs. baseline) after 3 months. Blood pressure was unchanged.